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Abstract
Background: Molecular tests for diagnosis of disease, particularly cancer, are gaining increased acceptance by physicians
and their patients for disease prognosis and selection of treatment options. Gene expression profiles and genetic mutations
are key parameters used for the molecular characterization of tumors. A variety of methods exist for mutation analysis but
the development of assays with high selectivity tends to require a process of trial and error, and few are compatible with
real-time PCR. We sought to develop a real-time PCR-based mutation assay methodology that successfully addresses these
issues.
Methodology/Principal Findings: The method we describe is based on the widely used TaqManH real-time PCR technology,
and combines Allele-Specific PCR with a Blocking reagent (ASB-PCR) to suppress amplification of the wildype allele. ASB-PCR
can be used for detection of germ line or somatic mutations in either DNA or RNA extracted from any type of tissue,
including formalin-fixed paraffin-embedded tumor specimens. A set of reagent design rules was developed enabling
sensitive and selective detection of single point substitutions, insertions, or deletions against a background of wild-type
allele in thousand-fold or greater excess.
Conclusions/Significance: ASB-PCR is a simple and robust method for assaying single nucleotide mutations and
polymorphisms within the widely used TaqManH protocol for real time RT-PCR. The ASB-PCR design rules consistently
produce highly selective mutation assays while obviating the need for redesign and optimization of the assay reagents. The
method is compatible with formalin-fixed tissue and simultaneous analysis of gene expression by RT-PCR on the same plate.
No proprietary reagents other than those for TaqMan chemistry are required, so the method can be performed in any
research laboratory with real-time PCR capability.
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Introduction
It is widely accepted that cancer is a genetic disease caused by
the accumulation of mutations and chromosomal aberrations [1].
Mutations in oncogenes and tumor suppressor genes determine
the phenotype of a tumor: its location, aggressiveness, and
sensitivity to therapeutics. Germ line mutations may predispose
to risk of developing cancer and influence the host response to the
tumor. The pathological features of virtually all tumors are driven
by acquisition of somatic (within tumor) mutations that alter
processes controlling cellular proliferation, mobility, and apoptosis
[2]. Detection of either germ line or somatic mutations has the
potential to influence decision-making in oncology. Increasingly,
somatic mutations have been proposed as biomarkers for cancer
prognosis and prediction of therapeutic efficacy. Recent examples
include the prediction of response [3–5] or resistance to certain
oncology drugs based on mutations in EGFR [6] or Kras [7–10].
This report describes a PCR-based assay that is well-suited for the
detection of either germ line or somatic mutations at a known base
position such as those that occur in Kras and BRAF.
Due to the cellular heterogeneity of most solid tumors, somatic
mutations in a gene can be present in low abundance within a very
high background of wild type sequence that may only differ from
mutant at a single nucleotide. Thus, detection of somatic
mutations poses a greater analytical challenge than detection of
germ line mutations. In this report we have adopted the
terminology of Liu and Sommer [11] for the analytical
characterization of mutation assays. Sensitivity is defined as the
minimum amount (number of copies or mass) of a template that
can be detected. The specificity of a mutation assay is the maximum
amount of a mismatched template that is undetectable and
selectivity is the relative assay response to the matched and
unmatched template. Selectivity is often expressed as a ratio or
percentage. For example, an assay that can detect 1 mutant
template in the presence of 100 wild type templates is said to have
a selectivity of 1:100 or 1%. Genotyping assays only need to have a
selectivity of 50%, that is, the assays must be able to detect 1
mutant template in the presence of one wild type template.
However, selectivity greater than 1:1000 might be required for
detection of clinically significant somatic mutations, for example,
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disease progression, and response to therapy [12,13].
Several methods exist for detection of somatic mutations by
real-time PCR. These methods include use of allele-specific
competitive blocker PCR [14], blocker–PCR [15,16], real-time
genotyping with locked nucleic acids [17,18], restriction enzymes
in conjunction with real-time PCR [19], and allele-specific kinetic
PCR in conjunction with modified polymerases [20]. Additional
methods include ARMS-PCR [21], TaqMAMA [22],and FLAG-
PCR [23]. These methods require either the use of modified bases,
special enzymes, or additional proprietary reagents or procedures.
We wished to develop a simple, robust, highly sensitive, and
selective method that is compatible with standard processes used
for gene expression analysis by real-time RT-PCR [24].
A widely used strategy for detecting DNA sequence variants is
allele-specific PCR in which one or both primers are designed to
anneal at sites of sequence variation [25]. Ideally, a primer whose
sequence matches a specific variant should selectively amplify only
that variant; however, in practice, significant mismatched amplifi-
cation typically occurs. It is common practice to anchor the 39 end of
the allele-specific primer at the mutant base in order to selectively
amplify the mutant template. This strategy reduces but does not
eliminate amplification of the wild-type allele. The amount of this
non-specific amplification has been found to vary widely depending
on the particular base mismatch between the allele-specific primer
and the wild-type sequence [18,26,27]. The variability of non-
specific amplification typically requires a process of trial and error
when designing highly selective mutation assays [18,21,22]. The
assay method reported here utilizes a combination of allele-specific
PCR primers, a blocker oligonucleotide to suppress amplification of
the wild type allele, and a set of reagent design rules that consistently
produce highly selective assays for a wide variety of single point
substitutions, insertions, or deletions. We refer to the modified assay
bytheacronymASB-PCR(Allele-SpecificBlockerPCR).Featuresof
the method include the ability to detect mutations in either DNA or
RNA with a high level of sensitivity and selectivity. No proprietary
reagents are required so the method can be performed in any
laboratory with real-time PCR capability. Moreover, the assay is
compatible with the process stream for real-time RT-PCR, enabling
mutation analysis to be carried out alongside gene expression
analysis of the same clinical specimen.
Mutations in Kras were chosen for the initial development and
characterization of the RT-PCR assay method based on their
clinical importance and high frequency in colorectal cancer. Kras
mutations are found in approximately 32% of colorectal tumors,
with eight single point substitutions accounting for the majority of
the mutations [28]. Kras mutations predict profound tumor
resistance to drugs that target the epidermal growth factor
receptor [7–10] and have also been associated with tumor stage
and risk of recurrence [28,29].
Materials and Methods
Sources of Nucleic Acids
Cell lines of known Kras genotype were obtained from ATCC
(Manassas,VA)(SW480,DLD-1,A549,MIAPaca-2,SW1116,Colo
320) or the European Collection of Cell Cultures (Wiltshire, UK)
(LS174T). RNA was extracted directly from frozen cell pellets using
an RNEasy kitH (QIAGEN, Valencia, CA) and quantitated by A260.
Colorectal cancer tumor RNA and DNA were extracted from serial
sections (3610 mm sections per extraction) of eighty-two formalin-
fixed paraffin-embedded (FPE) tissues obtained from ProteoGenex
(Culver City, CA) using an Epicentre MasterPure
TM kit (Madison,
WI)accordingtomanufacturer’sinstructions.RNAswerequantitated
by the RiboGreen AssayH and DNAs by the PicoGreen AssayH
(Invitrogen, Carlsbad, CA). Genomic DNA from HeLa cells was
purchased from BioChain (Hayward, CA). HeLa cell RNA was
purchased from Applied Biosystems/Ambion (Austin, TX).
Synthetic RNA templates for selected mutations were prepared
using a method for generating long templates from shorter
oligonucleotides [30]: Two synthetic oligonucleotides were
designed to be partially complementary at their 39 ends and have
a combined length that encompassed the mutation assay
amplicon. The oligonucleotides were denatured at 95uC for three
minutes and then cooled rapidly on ice. The products were
extended in a Klenow reaction containing 25 pmol annealed
oligonucleotidess, 5 Units Klenow Fragment (New England
Biolabs, Ipswich, MA), 1 mM dNTPs and 16 NEB2 Buffer
(New England Biolabs). A MegaShortscript
TM IVT reaction
(Applied Biosystems/Ambion) was performed in 20 mL according
to manufacturer’s instructions with one mL of a 1:5 dilution of
Klenow reaction. The IVT reaction was run at 37uC overnight
followed by treatment with 1 mL DNAseI at 37uC for 15 minutes.
Reactions were purified with an RNEasyH Kit (QIAGEN) and
IVT yield was determined by A260 and confirmed by limiting
dilution TaqManH assay [31]. A dilute synthetic DNA oligonu-
cleotide carrying the mutation G215C (Assay Mut6, see Table 1)
was obtained from Eurogentec North America (San Diego, CA).
Concentration was verified by limiting dilution TaqManH assay.
Oligonucleotide primers and probes were obtained from Integrat-
ed DNA Technologies (Coralville, IA).
TaqManH RT-PCR Assays
Reverse transcription was performed using an OmniScript RT
Kit (QIAGEN) according to the manufacturer’s instructions in a
10 mL volume with 50 nM of each reverse primer. TaqMan PCR
was performed with an RT volume of up to 1.25 mLi na5mL
assay with 16TaqMan Universal PCR Master Mix (no UNG)
TM
(Applied Biosystems, Foster City, CA), 900 nM primers, 200 nM
probe and 3600 nM blocker. One ng of RNA or 0.4 ng of DNA
extracted from FPET were analyzed in each PCR reaction, unless
noted otherwise. Standard TaqMan thermocycling conditions
were used: 10 min. at 95uC, 40 cycles of 20 sec. at 95uC, 45 sec. at
60uC. All PCR assays were run in triplicate or at higher replication
when deemed necessary.
A list of the oligonucleotides used for all of the PCR mutation
assays is provided in Table S1. Assays have been numbered for ease
of reference in the text. Assays that use the forward primer as the
discriminatingprimerareappendedwith‘‘.1’’andassaysthatusethe
reverse primer in this fashion are appended with ‘‘.2’’. PrimerEx-
press
TM (Applied Biosystems, Foster City, CA) was used for assay
design and estimation of oligonucleotide melting temperature.
Sequence Analysis
Bi-directional sequencing (one pass per direction) was performed
by SeqWright (Houston, TX) on 53 ProteoGenex FPE tissue gDNA
samples using dye-terminator chemistry (ABI BigDyeH v3.1) on an
ABI3730xlDNAsequencer.Basecallsweredeterminedmanuallyat
SeqWright according to the following rules: Minimum phred scores
of 20 were required to call bases. Traces were aligned to a reference
sequence and identical results were required in both forward and
reverse sequencing strands to make minor base calls. In the case
where only one sequence trace was available minor alleles were
called if the secondary peak was greater than 20% of the primary
peak Inall cases calling a minor alleleaspresent wasweighed against
the amount of noise in the immediate vicinity of the peak of interest.
SeqWright had no prior knowledge of sample genotypes as
determined by our assays.
Real-Time PCR Mutation Assays
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Description of the Assay Method
Wesoughttodevelopasetofassaydesignrulesthatwouldimprove
and standardize the performance of allele-specific PCR so that
amplification of primer:template mismatches would generally be
stronglysuppressed.Toaccomplishthis,twocriteriawereintroduced
into ourassay designs. Firstthemutant-specificprimer (Figure1)was
shortenedat its59-end toreduceitsTm toapproximately10uCbelow
the anneal/extend temperature of the assay. Second, a blocking
oligonucleotide, complementary to the wild type sequence but
phosphorylated at the 39-end to prevent extension, was added to
furthersuppressnonspecificamplificationofthewildtypeallelebythe
mutant-specific primer. The blocking reagent was designed to have
the variant base position approximately in the middle of the
oligonucleotide and to partially overlap the sequence of the mutant-
specificprimer.Twoadditionalreagents,asecondPCRprimeranda
Taqman Probe, are needed for real-time PCR of either the wild type
or variant template (although other detection systems such as SYBR
green or molecular beacons should also work).
Allele-Specific Primer Development with synthetic RNA
templates
In a published study of 1413 colon tumors [28] eight substitutions
accounted for 100% of the mutations found in Kras. Our initial
assay development experiments were carried out on the three most
commonly occurring mutations in Kras, G216T, G216A and
G219A (Table 1) representedbyassaysMut1.1,Mut2.1and Mut3.1,
respectively, all of which use the forward primer as the discriminat-
ing primer. The effect of primer Tm and concentration were
investigated for each of the assays using cDNA derived from
synthetic RNA templates. Reduction in concentration of the
discriminating primer from the standard 900 nM down to as low
as 28 nM did not improve assay selectivity and sometimes had
deleterious effects on sensitivity (data not shown). The Tm of the
allele-specific primer was varied by shortening the 59-end while
keeping the 39-end anchored on the variant base. For each assay,
eight allele-specific primers of differing lengths, ranging in Tm from
approximately50uCto6 0uC,weretestedusingsyntheticwildtypeor
mutant RNA templates. PCR cycling conditions were kept constant
at the manufacturer’s recommendation for TaqManH real-time RT-
PCR assays (see Methods; the recommended anneal/extend
temperature of 60uCwasmaintainedthroughoutthese experiments).
Results obtained with assay Mut1.1 using allele-specific primers with
Tm values between 50uCa n d5 6 uC are summarized graphically in
Figure 2A. When assay Mut1.1 was directed against a wild-type
RNA template, producing a 39 end allele-specific primer:template
mismatch of T:C, CT values increased as a function of decreasing
discriminating primer Tm.C T values were unchanged, however,
when the same primers were used to assay the mutant target (39 end
primer:template match of T:A). The difference in CT value (DCT)
between the wild type and mutant templates was largest at a primer
Tm of approximately 50uC. Very similar results were obtained when
allele-specific primer Tm was varied in the Mut2.1 and Mut3.1
assays(datanotshown).ThemaximumDCTforeachmutationassay
was obtained with a primer Tm of approximately 50uC, which
produced DCT values equal to 8.4, 11.5, and 10.0 for Mut1.1,
Mut2.1, andMut3.1,respectively. Because itisdifficulttopredictthe
Tm at which the sensitivity of an assay will be adversely affected, all
allele-specific primers were designed to have a Tm of approximately
50uC, which is 10uC below the anneal/extend temperature of the
standard cycling conditions. The effect of lower primer Tm,b e l o w
50uC, was investigated in a separate experiment using wild type and
mutant templates extracted from cell lines. At primer melting
temperatures below 50uCt h eDCT was sometimes unchanged but
frequently decreased due to a loss in sensitivity for detection of the
mutant templates (Figure S1).
Blocker Development with synthetic RNA templates
Because wild type allele abundance may occur in great excess
over the mutant target of interest in tumors we took further
measures to improve the assay selectivity. Blocking oligonucleo-
tides were synthesized that are both complementary to the wild
type allele at the position of the variant base and phosphorylated at
their 39 ends to prevent polymerase extension. These blocking
oligonucleotides were evaluated for their effect on selectivity using
synthetic wild type or mutant RNA templates in the Mut1.1,
Mut2.1, and Mut3.1 assays. Blockers were evaluated with respect
to concentration, length/Tm and position of the mutation in the
oligonucleotide. Blockers with the variant base position located
approximately in the middle of the oligonucleotide were found to
produce the best assay selectivity (data not shown).
We studied the effect of blocker Tm, ranging from approximately
50uCt o6 5 uC, on cross-amplification of a wild type template by a
mutant-specific primer. A Tm-dependent inhibition of wild type
template amplification was observed. An example of this effect is
Table 1. Kras mutations and their frequency in Colon Cancer.
Assay Name
Nucleotide
Substitution
Amino Acid
Change
Percent of Kras mutations in
Colon Cancer
a
Percent of Colon
tumors
b
Percent of tumors in
this study
c
Mut1 G216T G12V 22.7% 7.3% 13.4%
Mut2 G216A G12D 32.2% 10.3% 9.8%
Mut3 G219A G13D 21.6% 6.9% 9.8%
Mut4 G215A G12S 8.2% 2.6% 3.7%
Mut5 G215T G12C 9.9% 3.2% 4.9%
Mut6 G215C G12R 0.9% 0.3% 0%
Mut7 G216C G12A 4.0% 1.3% 0%
Total 99.6% 31.9% 41.5%
aData derived from Samowitz et al. [28]. Table values represent the frequency of the specified mutation as a percentage of total observed Kras mutations. The total is
not 100% because Samowitz et al. reported an additional mutation at a frequency of 0.4%.
bThe frequency of the specified mutation calculated as a percentage of total tumor specimens tested by Samowitz et al. [28]. Four of 449 tumors had two mutations.
cDetermined in DNA extracted from 82 formalin-fixed paraffin-embedded colorectal cancer specimens.
doi:10.1371/journal.pone.0004584.t001
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primerandsevendifferentblockingoligonucleotides.Assayselectivity
was improved by up to 3.7 CT units by the use of blockers with Tm
greaterthanorequaltoapproximately57uC.Theslightdipobserved
withthe59.4uCblockerwastheonlyanomalyandlikelywastheresult
of high variability associated with high CT values. Decreased
sensitivity for detection of the mutant template was only seen when
theblockerTmwas2uCormorehigherthanthePCRanneal/extend
temperature (60u). Similar effects of blocker Tm on amplification of
mutant and wild type templates were observed for the Mut2.1 and
Mut3.1 assays (data not shown). For all three mutation assays, the
combination of a blocker with Tm of at least 54uC and allele-specific
primer with Tm of approximately 50uC produced the greatest
selectivity without measurable losses in sensitivity.
We checked the variability of wild type template inhibition as a
function of blocker concentration for the Mut1.1, Mut2.1 and
Mut3.1 assays. An increasing dose-dependent inhibition of ampli-
fication was observed up to approximately 3.6 mMb l o c k e r
concentration and reached a plateau at about 8 CT.W i l dt y p e -
specific blockers had no effect on mutant synthetic RNA
amplification at concentrations as high as 14.4 mM (data not shown).
Blockers designed with the variant base position approximately in
the middle of the oligonucleotide and a Tm approximately equal to
the anneal/extension temperature improved the selectivity of ASB-
PCR assays for those Kras mutations that had a DCT less than ,11
using a low Tm primer alone (Table 2).
The value of including a blocker in eleven ASB-PCR assays was
examined using wild type and mutant templates extracted from
cell lines (Figure S1). The presence of a blocker improved assay
selectivity for eight of the assays by increasing the CT for detection
of the wild type template. For the three assays where inclusion of a
blocker did not improve assay selectivity no deleterious effect on
the assay was observed. Therefore, we chose to include blockers in
the standardized assay design rules described below.
Standardized Assay Design Rules
Standardized design rules (Table 3) were developed for ASB-
PCRassaysbasedonthetestswithsyntheticRNAsdescribed above.
The goal of these rules was to design assayswithselectivity of 1:1000
or more on the first design without a need for additional
Figure 1. Diagram to illustrate the assay method.
doi:10.1371/journal.pone.0004584.g001
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primer that is 10uC below the anneal/extend temperature in the
cycling conditions, 2) a non-extendable blocker, specific for the wild
type sequence, with the variant base position approximately in the
middle of the oligonucleotide, 3) a blocker Tm approximately equal
to but not greater than the cycling anneal/extend temperature, and
4) a blocker concentration that is 4-fold greater than that of the
allele-specific primer. In addition, blocker oligonucleotides that are
developed for use in a TaqManH -based system may overlap with
thefluorescent probebya fewbases. Theserules were used to create
Figure 2. Optimization of allele-specific primer and blocker Tm. CT values are for the Kras Mut1.1 assay (G216T). A mutant-specific primer was
used to assay either a wild type or mutant RNA template. Circles represent response to wild type synthetic RNA. Squares represent response to
mutant synthetic RNA. Error bars represent 95% confidence intervals. The final version of this assay included a blocker oligonucleotide with a Tm of
60.8uC and a variant-specific primer with a Tm of 50uC. A. The effect of primer Tm on variant-specific assay CT. B. The effect of blocker oligonucleotide
Tm on variant-specific assay CT.
doi:10.1371/journal.pone.0004584.g002
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and G219A using the reverse primer as the allele-specific primer
(assays Mut1.2, Mut2.2 and Mut3.2, respectively). In addition, we
chose to develop assays targeting four Kras mutations (Mut4-7,
Table 2) based on their frequency in solid tumors and association
with resistance to anti-EGFR therapeutics [8,28,29].
Assay Performance in Cell Line RNA or DNA
All of the Kras mutation assays were tested with and without the
blocker and allele-specific primer modifications as specified in the
design rules to determine the effects these modifications have on
assay selectivity. For Assays Mut1-5 and Mut7 these experiments
were conducted using RNA extracted from cell lines of known
Kras genotype. Cell lines carrying the G215C (Mut6) mutation
were unavailable; the performance of Assay Mut6 was evaluated
using synthetic mutant DNA in conjunction with wild type DNA
obtained from HeLa cells. The results are summarized in Table 2.
The difference in CT (DCT) between wild type and mutant
template CT values which serves as an approximation of assay
selectivity was increased when either blockers or low Tm
discriminating primers were introduced to the assays. In most
cases the magnitudes of these effects were approximately additive;
the largest increases in DCT occurred when these modifications
were used in combination. In the three cases where the effects did
not appear to be additive, Mut1.2, Mut6.1 and Mut7.1, the un-
modified versions of the assays (no blockers or low Tm primers)
already exhibit a high degree of selectivity.
Assay selectivity was estimated by serially diluting RNA
extracted from mutant cell lines into RNA extracted from wild
type cell lines (Table 4). The mass of wild type RNA was divided
by the mass of mutant RNA to calculate an approximate ratio of
wild type to mutant alleles at each dilution. The selectivity of each
assay was estimated by determining the intersection of the upper
95% confidence interval of the regression of observed CT response
on mutant RNA serial dilution with the lower 95% confidence
limit of the observed CT response of a wild type-only RNA control.
The amount of mutant RNA was estimated by interpolation from
the best-fit line at this intersection. The total amount of RNA
Table 2. Effect of Reagent Design on Mutation Assay Performance in Cell Line RNA or DNA.
Assay Name
b Primer:Template mismatch Allele-specific primer only
c +Blocker
d +Low Tm primer
e +Both
f
DCT
a
Mut1.1 T:C 1.3 8 10.4 15.6
Mut1.2 A:G 8.3 14.1 15.3 15.5
Mut2.1 A:C 2.3 8.4 11.5 13.3
Mut2.2 T:G 1.4 5.5 8.1 11.6
Mut3.1 A:C 0.8 2.7 9.9 13.3
Mut3.2 T:G 20.3 20.3 4.6 7.5
Mut4.2 T:G 20.7 0.4 5.5 9.1
Mut5.1 A:G 1.8 7 7.9 13.8
Mut6.1
g G:G 11.5 14.4 16.3 16.1
Mut7.1 G:G 10.3 12.8 15.7 15.4
aDCT is the difference in CT obtained from wild type and mutant templates in the allele-specific mutation assay.
bAssay names ending in ‘‘.1’’ were designed with the forward primer to be specific for the mutant sequence and assay names ending in ‘‘.2’’ were designed with the
reverse primer specific for the mutant sequence.
cDCT obtained when an allele-specific primer with Tm about 60u was used without a blocker.
dDCT obtained when a blocker was used in combination with an allele-specific primer.
eDCT obtained when a low Tm allele-specific primer was used.
fDCT obtained when both a blocker and low Tm allele-specific primer were used in combination.
gSynthetic mutant DNA was used for Assay Mut6.1 due to the unavailability of cell lines carrying this mutation. Wild type DNA was obtained from HeLa cells.
doi:10.1371/journal.pone.0004584.t002
Table 3. ASB-PCR Design Rules.
Reagent Properties
Allele-Specific Primer 1. either the forward or reverse primer
2. 39-end is anchored on the variant base
3. Tm is 10uC below PCR extension temperature
Blocker 1. Designed to same strand as the allele-specific primer
2. Discriminating base is approximately in the middle of the oligonucleotide
3. Complementary to the wild type sequence
4. Not extendable by polymerases (phosphorylated on 39-end)
5. Tm is approximately equal to, but not greater than, the PCR extension temperature
6. Used at 46the concentration of the allele-specific primer
doi:10.1371/journal.pone.0004584.t003
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determine the selectivity of the assay. In all cases the assays had
selectivities of 1:1000 or greater. Mutant RNA inputs between 2 to
250 pg could be discriminated from a thousand-fold or greater
excess of wild type RNA, depending on the assay tested. (These
estimates of assay selectivity were conservative because most of the
mutant RNA cell lines used in this mixture study were
heterozygous for mutant alleles and as such had approximately
half as many mutant alleles per unit mass of total RNA as
compared with a homozygous mutant The one exception was cell
line SW480 which was homozygous for the G216T mutation. The
effect of heterozygosity was not accounted for in the calculations
summarized in Table 4.)
Amplification plots of the real-time background-corrected
fluorescence versus PCR cycle number for assay Mut1.2 are
shown in Figure 3A. A dose-dependent shift of the amplification
curves to the right was observed with increasing dilution of the
sample. In our laboratory, the CT is defined as the PCR cycle
number at which the amplification curve exceeds a background-
corrected fluorescence of 0.2. These data illustrate that the
amplification curve for the 1:1024 dilution was easily resolved
from the sample containing only wild type RNA.
The selectivity of the mutation assays was also indicated by the
relative dose-response characteristics of mutant and wild type
RNA. An example, shown in Figure 3B, is the titration of mutant
(SW480) and wild type (COLO 320) RNA in the Mut1.2 (G216T)
mutation assay. Even the highest concentration of wild type RNA
tested did not produce a CT that was significantly different from
40.
Assay Performance in Formalin-Fixed Tumor Specimens
We sought to assess the performance of ASB-PCR assays with
both blockers and low Tm primers by genotyping DNA from
formalin-fixed paraffin-embedded (FPE) tissue specimens. FPE
specimens typically contain fragmented and chemically modified
nucleic acid [24]. Seven Kras mutations were evaluated in DNA
extracted from 82 FPE colorectal tumor specimens of unknown
Kras status. Mutation status assignments were made by comparing
mutant CT assay values in the FPE samples to a classification line
obtained using serial dilutions of wild type HeLa cell DNA. The
classification line was derived as the lower bound of the 95%
prediction interval from a regression model estimated using data
from the HeLa wild type control. Samples that produced mutant
assay CT values below the classification line were called present for
that mutation. The frequency of mutations detected by the ASB-
PCR assay (Table 1) was similar to data reported by other
investigators using different methods [28]. Sufficient DNA was
available from 53 of the 82 samples for confirmatory DNA
sequencing. The quality of DNA from 44 of the 53 samples was
sufficient for sequencing. Mutation calls by ASB-PCR were highly
concordant with sequence analysis with a statistical sensitivity and
selectivity of 100% and 92.6%, respectively. Allele calls obtained
by ASB-PCR for each of the individual mutation assays and by
sequence analysis are summarized in Table S2.
Two samples that typed positive by ASB-PCR, for substitu-
tions G216T and G219A, were negative by sequence analysis
(Table S2). Several lines of evidence suggest that these discordant
samples did, in fact, harbor Kras mutations. First, the CT values
obtained for these samples in the Mut1 and Mut3 assays clearly
distinguished them from wild type specimens. The CT values
from ASB-PCR analysis of all 44 samples are depicted
graphically in Figures 4 A–C. The CT values from assays with
the mutant alleles are on the Y-axes and those from assays with
the wild type allele are on the X-axes. Both discordant samples
(triangles in Figures 4A and 4C) cluster with other mutation
positive samples and are well-separated from the classification
line for the wild type population. Second, the mutation calls for
these samples made from the sequencing electropherograms were
complicated by experimental noise that may have resulted from
poor sample quality (data not shown). In addition, for one of the
discordant samples sequencing data was only obtained from one
strand of the sequencing template. Inspection of the electrophe-
rograms for these samples in fact revealed minor peaks that are
consistent with the presence of the mutations called by ASB-
PCR. Third, as described below, ASB-PCR analysis of RNA
extracted from the same samples confirmed the mutation calls
made by ASB-PCR analysis of DNA. Taken together, these
results support the view that the two discordant samples were
true positives for Kras mutations that were undetected by
sequence analysis.
Table 4. Performance of Mutation Assays using RNA or DNA Extracted from Cell Lines.
Assay Name
Cell Line Mixture
(Mutant/Wild Type)
Mutation Assay Result: Mixed
Cell Lines
Mutation Assay Result:
Wild type Cell Line DCT Selectivity
CT SD CT SD
Mut1.2
a SW480/COLO 320 25.8 0.45 36.7 0.38 10.9 1,600
Mut2.1
a LS174T/HeLa 26.1 0.27 38.6 1.22 12.5 1,000
Mut3.1
a DLD-1/HeLa 23.7 0.16 37.7 1.84 14 1,000
Mut4.2
a A-549/HeLa 24.6 0.25 36.3 0.88 11.7 1,500
Mut5.1
a MIA PaCa-2/HeLa 25.1 0.37 39.6 0.68 14.5 9,000
Mut6.1
b synthetic/HeLa DNA 23.6 0.04 40 0 16.4 15,625
Mut7.1
a SW1116/HeLa 23.1 0.62 40 0 16.9 32,000
aThe CT and standard deviation (SD) comparing a 50/50 wild type/mutant cell line mixture (32 ng each) with wild type alone (32 ng) using the indicated assay. Wild type
cell lines used were either COLO 320 or HeLa, depending on availability at the time. Cell line SW480 is homozygous for Mut1 (G216T); all other cell lines are
heterozygous for the indicated mutations. Linearity of all assays ranged from 0.992–0.999. Efficiency for all assays ranged from 92%–116%. DCT is the difference
between the CT obtained from Wild Type Cell Line CT – Mixed Cell Line CT. Selectivity was measured as described in Results.
bThe CT and standard deviation (SD) comparing a 50/50 wild type cell line DNA/mutant synthetic DNA (15,625 copies each) mixture with wild type DNA alone (15,625
copies) using the Mut6.1 assay. Synthetic mutant DNA was used for Assay Mut6.1 as no cell line carrying this mutation was available. Limiting Dilution Assay analysis
was used to determine the number of copies of synthetic template as well as the number of wild type Kras alleles in HeLa DNA.
doi:10.1371/journal.pone.0004584.t004
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Using ASB-PCR for mutation analysis of RNA has the
advantages that only one nucleic acid extraction is needed and
the RNA can be processed for gene expression analysis of the same
samples. Therefore, we wanted to compare the concordance of
results from ASB-PCR analysis of DNA and RNA extracted from
the same clinical specimens. RNA was extracted from 72 of the
original 82 colorectal cancer FPE tissue specimens described above
(the remaining samples having been depleted) and ASB-PCR
assays for all Kras mutations were carried out. Figures 5 A–C show
scatter plots of RNA vs. DNA CT values for assays Mut1, Mut2
and Mut3, representing three of five mutation assays for which
mutation-positive samples were identified. Two distinct clusters
were observed for each assay, indicating concordance of mutation
assignments in RNA and DNA extracts. Assays Mut4 and Mut5
also produced clusters very similar to those shown in Figure 5 (data
not shown).
Discussion
The ASB-PCR mutation detection method reported here has
features that distinguish it from other mutation assays. Principal
among these features is the high level of selectivity possible without
the need for proprietary reagents other than those normally
required for TaqManH real-time PCR. The assay design rules
reported here, combining the use of an oligonucleotide blocker
with an allele-specific PCR primer, consistently produced
mutation assays with selectivity greater than 1:1000 which was
an improvement over the selectivity achieved using allele-specific
primers alone. Moreover, the reagents and workflow process for
the ASB-PCR method is compatible with standard protocols for
real-time RT-PCR, enabling mutation analysis to be performed
alongside gene expression assays of the same samples using a single
technology platform. This last point is significant because gene
expression profiles generated by RT-PCR have proven to be
diagnostically valuable in clinical practice [32].
Combining competitive blockers with allele-specific PCR
primers overcomes one of the major limitations of mutation
detection that relies on allele-specific primers alone. Several studies
have addressed the effect of primer:template mismatches on the
efficiency of extension by Taq or other polymerases [18,27]. The
general consensus that has emerged is that purine-pyrimidine
(A:C, C:A, G:T, T:G) and pyrimidine-pyrimidine (T:C, C:T, T:T,
C:C) mismatches extend efficiently whereas purine-purine (A:G,
G:A, A:A, G:G) mismatches do not. Consistent with these earlier
reports, our assays Mut1.2 (A:G mismatch), Mut7.1 and Mut6.1
(both G:G mismatch), exhibit very high selectivity using only
allele-specific primers, as expected for purine-purine mismatches.
The primer:template mismatch of T:G was found by Lattora et al.
[18] to be the most permissive mismatch in terms of Taq extension
in PCR. Likewise, assays Mut2.2, Mut3.2 and Mut 4.2 (all T:G
mismatch) exhibit very poor selectivities in their unmodified forms
and proved the most refractory to improvement from low Tm
primers. Competitive blocker oligonucleotides of various types
have been used by several investigators to suppress amplification of
mismatched templates in PCR [14,15,33,34]. We evaluated non-
extendable oligonucleotide blockers with the discriminating base
located approximately in the center of the sequence in order to
maximize the Tm difference between matched and mismatched
templates [35]. Blockers of this type improved discrimination for
most, but not all, of our assays. Low Tm primers and blockers used
in combination produced the greatest benefit in terms of selectivity
(average DCT=13.1) without measurable losses in sensitivity.
Two features of our competitive blocker oligonucleotides
contributed to their effectiveness in suppressing amplification of
wild type templates: first, the location of the discriminating base in
the middle of the blocker sequence; second, the partial overlap
with the sequence of the allele-specific primer. Blockers based on
this principle preferentially bind perfectly-matched templates and
inhibit binding of mismatched primers. We showed that perfectly-
matched primers were refractory to inhibition by blockers over a
wide Tm range. In our studies discrimination was improved when
blockers were used in conjunction with low Tm primers and,
importantly, extension from the permissive T:G mismatches
(assays Mut2.2, Mut 3.2 and Mut 4.2) was further suppressed by
at least 3 CTs when blockers were added.
Having the option to use either the forward or reverse primer as
the allele-specific primer increases the opportunity to develop an
optimal ASB-PCR assay. Knowledge of the primer:template
mismatch can aid in selection of the allele-specific primer (forward
vs. reverse) as illustrated by our variable results obtained with the
two versions of the Kras Mut3 assay. In most cases in the current
Figure 3. Sensitivity and selectivity of the Mut1.2 assay. A.
Detection of cell line RNA containing Kras G216T mutant diluted into
wild type cell line RNA using the Kras Mut1.2 assay. DRn is the difference
between the normalized fluorescence of the TaqMan reporter probe at
each PCR cycle and the background fluorescence measured during the
first 15 PCR cycles. Each curve represents the time course of PCR assays
(average of triplicate measurements) at each dilution. The horizontal
line at DRn=0.2 represents the threshold for determination of CT for the
individual amplification curves. B. Serial-dilutions of RNA extracted from
wild type COLO320 (filled squares) and mutant SW480 (filled circles) cell
lines submitted to the Kras Mut1.2 assay. Error bars represent 2 times
the standard deviation of triplicate determinations.
doi:10.1371/journal.pone.0004584.g003
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of the assay, suggesting that the method is robust and independent
of sequence context. This is important because the design of ASB-
PCR assays is constrained by the need to encompass the sequence
surrounding the variant base.
A noteworthy feature of ASB-PCR is the consistently high level
of selectivity obtained using the assay design rules described
herein. In addition to the Kras mutation assays reported here we
have used the ASB-PCR assay design rules to develop assays for 13
different mutations in BRAF, PIK3CA, p53, and CYP2D6. With
the exception of an assay for a mutation in BRAF (T600A) all of
the assays have selectivity greater than 10 DCT. The BRAF
T600A assay, in which the forward primer is allele-specific, has
selectivity of 6.5 DCT (A:A mismatch) whereas the assay in which
the reverse primer is allele-specific, has selectivity of 15 DCT (T:T
mismatch). Thus, consistently high selectivity mutation assays can
be developed using the ASB-PCR design rules without the need
for multiple cycles of reagent design and optimization.
The utility of ASB-PCR assays for analysis of nucleic acids
extractedfromFPEtissuesisofparticularinterest.Previously,wehave
noted the value of archived FPE specimens for discovery of gene
expression profiles that predict clinical outcomes [24,32,36]. The
ASB-PCR assay method reported here enables mutation analysis in
the same archival specimens used for profiling gene expression.
Severallinesofevidencesupportthevalidityofourmutationassaysfor
RNA extracted from FPE tissue specimens. First, the frequency of
mutations we observed in colorectal tumors was similar to the
frequency determined by sequencing in colon cancer [28]. Second,
theresultsfromASB-PCRassaysofnucleicacidsextractedfromFPE
specimens were highly concordant with analysis of the same
specimens by conventional Sanger sequencing. Third, analyses of
RNA and DNAextractedfrom the sameFPE specimens were highly
concordant.It hasbeenwidelyreported that deaminationofcytosine
or adenine caused by formalin fixation produces uracil and
hypoxanthine residues in their place, respectively, resulting in what
appear to be C:T (G:A) or A:G (T:C) transition mutations [37,38].
Thesealterationsareindistinguishablefrombiologicalmutationswith
the exception of uracil formation in genomic DNA which can be
ablatedbypre-treatmentwithuracil-N-glycosylase[39].Wehavealso
observed a high frequency of randomly distributed C–T transitions,
presumablytheresultofformalin-induceddeamination,inresequen-
cing of nucleic acids extracted from FPE specimens (unpublished
observations). These transitions are more common in RNA than
DNA but were never present at a frequency greater than 2% at any
given base position. The high level of concordance of our ASB-PCR
resultswithRNAandDNAextractedfromthesameFPEspecimensis
evidence that the mutations we detect are not the result of formalin-
induced deamination.
The ability to detect mutations in RNA potentially provides
additional information not possible to discern from analysis of
DNA. Several investigators have noted that differential expression
of alleles is common in the human genome [40–42]. Hodgson and
coworkers [43] reported that RNA extracted from breast tumors
was enriched by as much as 10,000-fold for mutant p53 sequences
Figure 4. Comparison of mutation detection by ASB-PCR and
nucleic acid sequencing. ASB-PCR results are shown for the 44
randomly-selected FFPE colorectal tumor specimens for which
sequencing data were available. Genomic DNA extracted from 44
randomly-selected FFPE colorectal tumor specimens was submitted to
ASB-PCR assays A) Kras G216T, assay Mut1.1, B) Kras G216A, assay
Mut2.1, and C) Kras G219A, assay Mut3.1. In each graph the CT values
measured in the wild type Kras assay (x-axis) is plotted vs. the CT values
measured in the specified Kras variant allele assay (y-axis). Samples were
assayed at 0.4 ng of DNA per well. The solid line represents the
classification boundary, which was derived as the lower 95% prediction
limit of a linear regression of variant-specific assay CT response on a
titration of wild type samples submitted to the variant-specific assay.
Error bars represent 95% confidence limits based on a pooled estimate
of standard error for all samples with a mean CT less than 35. Note that
samples for which the 95% confidence intervals overlapped were
designated as wild type. Circles: (O) Samples called wild type by both
PCR and sequencing; Squares (%): samples called mutant by both PCR
and sequencing; Triangles (n): samples called mutant by PCR but wild
type by sequencing.
doi:10.1371/journal.pone.0004584.g004
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did not observe a similar enrichment of Kras mutations in RNA as
compared with DNA in colorectal tumors, suggesting that
generalizations regarding differential expression of mutant alleles
are not possible. Further studies are needed to determine if
differential expression of mutant alleles, such as those reported for
p53, correlate with clinical outcomes.
Finally, it is noteworthy that evidence for the practical clinical
utility of the assay methodology described here and applied to FPE
tissue RNA has recently been presented. Specifically, the Kras
mutation assays described above were used to screen tumor RNA
from metastatic colon cancer patients prior to their treatment with
the anti-EGFR monoclonal antibody Cetuximab, and have
demonstrated a profoundly strong correlation between presence of
Kras mutation and failure to respond to this therapeutic agent [44].
Supporting Information
Table S1 Summary of assay oligonucleotide components.
Sequences are listed in 59-39 order from left to right. Discrimi-
nating primers are underlined with 39 bases in boldface. Locked
Nucleic Acids (LNAs) are represented by capital letters. PO4: 39-
phosphate. Melting temperatures (Tms) were determined using the
Primer Express
TM software package. The region of Kras against
which assays were designed is also shown with codons 12 and 13
listed in boldface. NA: Not Applicable.
Found at: doi:10.1371/journal.pone.0004584.s001 (0.06 MB
DOC)
Table S2 Mutation calls by ASB-PCR analysis and sequencing
Found at: doi:10.1371/journal.pone.0004584.s002 (0.03 MB
DOC)
Figure S1 CT response as a function of discriminating primer
Tm. PrimerTms were altered bylengthening orshortening from the
59 end while keeping the 39 end anchored on the variant site. Primer
lengths varied from 13–23 bases. Sixty nanograms cell line RNAs
were used as template for assays Mut1-Mut5 and Mut7. Thirty
nanograms HeLa DNA (wild type template) or 27,300 copies
synthetic DNA (mutant template) were used for assay Mut6. Squares
represent the indicated assay applied to mutant template. Circles
represent the indicated assay applied to wildtype template. Filled
symbols represent assays without blocker added. Open symbols
represent assays with 3600 nM blocker. A.RFinal Mut1.1 assay:
50uC discriminating primer Tm with blocker. B.RFinal Mut2.1
assay: 48.9uC discriminating primer Tm with blocker. C.RFinal
Mut3.1 assay: 45uC discriminating primer Tm with blocker.
D.RFinal Mut4.1 assay: 50.6uC discriminating primer Tm with
blocker. E.RFinal Mut5.1 assay: 50.2uC discriminating primer Tm
with blocker. F.RFinal Mut6.1 assay: 50.5uC discriminating primer
Tm with blocker. G.RFinal Mut7.1 assay: 51.4uC discriminating
primer Tm with blocker. H.RFinal Mut1.2 assay: 49.7uC
discriminating primer Tm with blocker. I.RFinal Mut2.2 assay:
48.5uC discriminating primer Tm with blocker. J.RFinal Mut3.2
assay: 45.3uC discriminating primer Tm with blocker. K.RFinal
Mut4.2 assay: 50.6uC discriminating primer Tm with blocker.
Found at: doi:10.1371/journal.pone.0004584.s003 (0.23 MB
DOC)
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